Salvage radiation therapy following radical prostatectomy in Stockholm County in 2008–2016
- 28 Downloads
This is a large single-institution report including 714 consecutive prostate cancer patients who received salvage radiation therapy (SRT) between 2008 and 2016 in Stockholm, Sweden. The aim of the study was to determine the PSA outcomes of salvage radiotherapy in a cohort of prostate cancer patients after radical prostatectomy (RP).
All patients have been treated with 70 Gy during a 7-week period. STHLM-0 database was the source of all PSA test results in Stockholm.
During a median follow-up of 48 months after radiotherapy treatment, 49% of patients had no signs of biochemical failure (BcF), 13% experienced BcF, and 38% never reached PSA nadir and subsequently progressed after SRT. Five-year biochemical free survival (bPFS) was 47%. Low PSA at SRT start as well as low preoperative Gleason score and T-stage were independently associated with favorable 5-year biochemical progression-free survival.
Patients who started SRT at PSA < 0.28 ng/ml had the best 5-year bPFS of 58%. Median pre-SRT PSA was 0.28 ng/l (0.2–0.45) indicating the good standard of salvage radiotherapy process from patient referral to start of radiotherapy in Stockholm County.
KeywordsSalvage Radiotherapy Prostate Cancer
The authors appreciate the kind help of Carina Holmberg, Eva Onjukka, Berit Wennberg, Andreas Pettersson, colleagues from the former urosektionen, Mattias Hedman, professor Sten Nilsson, and professor Henrik Grönberg.
Compliance with ethical standards
No funding support is associated with this study.
Conflict of interest
The authors declare that they have no conflict of interest.
This article does not contain any studies with human or animal subjects performed by any of the authors. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Ethical permission to conduct the study has been granted in 2012 (Dnr: 2012/438-31/3) and prolonged in 2018 (Dnr: 201/568-32) [17, 19].
Informed consent regarding all individuals participating in the study is subjected to coverage by the national Swedish ethical permissions (Dnr: 2012/438-31/3) and (Dnr: 201/568-32) obtained specifically for the purposes of this study.
- 1.Samverkan RCi (2016) Prostatacancer. Årsrapport från Nationella prostatacancerregistret 2015Google Scholar
- 4.Rajan P, Hagman A, Sooriakumaran P, Nyberg T, Wallerstedt A, Adding C, Akre O, Carlsson S, Hosseini A, Olsson M, Egevad L, Wiklund F, Steineck G, Wiklund NP (2016) Oncologic outcomes after robot-assisted radical prostatectomy: a large European single-centre cohort with median 10-year follow-up. Eur Urol Focus 4:351–359. https://doi.org/10.1016/j.euf.2016.10.007 CrossRefGoogle Scholar
- 5.Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, van der Poel HG, van der Kwast TH, Rouviere O, Wiegel T, Mottet N (2017) EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol 71(4):630–642. https://doi.org/10.1016/j.eururo.2016.08.002 CrossRefGoogle Scholar
- 6.Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G, Canby-Hagino E, Crawford ED (2009) Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 181(3):956–962. https://doi.org/10.1016/j.juro.2008.11.032 CrossRefGoogle Scholar
- 7.Bolla M, van Poppel H, Tombal B, Vekemans K, Da Pozzo L, de Reijke TM, Verbaeys A, Bosset JF, van Velthoven R, Colombel M, van de Beek C, Verhagen P, van den Bergh A, Sternberg C, Gasser T, van Tienhoven G, Scalliet P, Haustermans K, Collette L (2012) European organisation for R, treatment of cancer RO, Genito-urinary G (2012) postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet 380(9858):2018–2027. https://doi.org/10.1016/S0140-6736(12)61253-7 CrossRefGoogle Scholar
- 8.Wiegel T, Bartkowiak D, Bottke D, Bronner C, Steiner U, Siegmann A, Golz R, Storkel S, Willich N, Semjonow A, Stockle M, Rube C, Rebmann U, Kalble T, Feldmann HJ, Wirth M, Hofmann R, Engenhart-Cabillic R, Hinke A, Hinkelbein W, Miller K (2014) Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial. Eur Urol 66(2):243–250. https://doi.org/10.1016/j.eururo.2014.03.011 CrossRefGoogle Scholar
- 10.Chade DC, Eastham J, Graefen M, Hu JC, Karnes RJ, Klotz L, Montorsi F, van Poppel H, Scardino PT, Shariat SF (2012) Cancer control and functional outcomes of salvage radical prostatectomy for radiation-recurrent prostate cancer: a systematic review of the literature. Eur Urol 61(5):961–971. https://doi.org/10.1016/j.eururo.2012.01.022 CrossRefGoogle Scholar
- 13.Goenka A, Magsanoc JM, Pei X, Schechter M, Kollmeier M, Cox B, Scardino PT, Eastham JA, Zelefsky MJ (2012) Long-term outcomes after high-dose postprostatectomy salvage radiation treatment. Int J Radiat Oncol Biol Phys 84(1):112–118. https://doi.org/10.1016/j.ijrobp.2011.10.077 CrossRefGoogle Scholar
- 14.Shipley WU, Seiferheld W, Lukka HR, Major PP, Heney NM, Grignon DJ, Sartor O, Patel MP, Bahary JP, Zietman AL, Pisansky TM, Zeitzer KL, Lawton CA, Feng FY, Lovett RD, Balogh AG, Souhami L, Rosenthal SA, Kerlin KJ, Dignam JJ, Pugh SL, Sandler HM, RTOG NRGO (2017) Radiation with or without antiandrogen therapy in recurrent prostate cancer. N Engl J Med 376(5):417–428. https://doi.org/10.1056/NEJMoa1607529 CrossRefGoogle Scholar
- 15.Carrie C, Hasbini A, de Laroche G, Richaud P, Guerif S, Latorzeff I, Supiot S, Bosset M, Lagrange JL, Beckendorf V, Lesaunier F, Dubray B, Wagner JP, N'Guyen TD, Suchaud JP, Crehange G, Barbier N, Habibian M, Ferlay C, Fourneret P, Ruffion A, Dussart S (2016) Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial. Lancet Oncol 17(6):747–756. https://doi.org/10.1016/S1470-2045(16)00111-X CrossRefGoogle Scholar
- 16.Mohler J, Bahnson RR, Boston B, Busby JE, D'Amico A, Eastham JA, Enke CA, George D, Horwitz EM, Huben RP, Kantoff P, Kawachi M, Kuettel M, Lange PH, Macvicar G, Plimack ER, Pow-Sang JM, Roach M 3rd, Rohren E, Roth BJ, Shrieve DC, Smith MR, Srinivas S, Twardowski P, Walsh PC (2010) NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Cancer Netw 8(2):162–200CrossRefGoogle Scholar
- 17.Aly M, Dyrdak R, Nordstrom T, Jalal S, Weibull CE, Giske CG, Gronberg H (2015) Rapid increase in multidrug-resistant enteric bacilli blood stream infection after prostate biopsy - a 10-year population-based cohort study. Prostate 75(9):947–956. https://doi.org/10.1002/pros.22979 CrossRefGoogle Scholar
- 18.Nordstrom T, Aly M, Clements MS, Weibull CE, Adolfsson J, Gronberg H (2013) Prostate-specific antigen (PSA) testing is prevalent and increasing in Stockholm County, Sweden, despite no recommendations for PSA screening: results from a population-based study, 2003-2011. Eur Urol 63(3):419–425. https://doi.org/10.1016/j.eururo.2012.10.001 CrossRefGoogle Scholar
- 19.Nordstrom T, Bratt O, Ortegren J, Aly M, Adolfsson J, Gronberg H (2016) A population-based study on the association between educational length, prostate-specific antigen testing and use of prostate biopsies. Scand J Urol 50(2):104–109. https://doi.org/10.3109/21681805.2015.1113200 CrossRefGoogle Scholar
- 20.Cortes-Gonzalez JR, Castellanos E, Sandberg K, Eriksson MH, Wiklund P, Carlsson S, Cohn-Cedermark G, Harmenberg U, Gustafsson O, Levitt SH, Lennernas B, Brandberg Y, Marquez M, Kalkner KM, Nilsson S (2013) Early salvage radiation therapy combined with short-term hormonal therapy in recurrent prostate cancer after radical prostatectomy: single-institution 4-year data on outcome, toxicity, health-related quality of life and co-morbidities from 184 consecutive patients treated with 70 Gy. Int J Oncol 42(1):109–117. https://doi.org/10.3892/ijo.2012.1694 CrossRefGoogle Scholar
- 21.American Society for Therapeutic Radiology and Oncology Consensus Panel (1997) Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys 37(5):1035–1041Google Scholar
- 23.Briganti A, Karnes RJ, Joniau S, Boorjian SA, Cozzarini C, Gandaglia G, Hinkelbein W, Haustermans K, Tombal B, Shariat S, Sun M, Karakiewicz PI, Montorsi F, Van Poppel H, Wiegel T (2014) Prediction of outcome following early salvage radiotherapy among patients with biochemical recurrence after radical prostatectomy. Eur Urol 66(3):479–486. https://doi.org/10.1016/j.eururo.2013.11.045 CrossRefGoogle Scholar
- 25.Henkenberens C, Derlin T, Bengel FM, Ross TL, Wester HJ, Hueper K, Kuczyk MA, Christiansen H, von Klot CA (2018) Patterns of relapse as determined by (68)Ga-PSMA ligand PET/CT after radical prostatectomy : importance for tailoring and individualizing treatment. Strahlenther Onkol 194(4):303–310. https://doi.org/10.1007/s00066-017-1231-9 CrossRefGoogle Scholar